Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
18 mars 2021 16h05 HE
|
Progenity, Inc.
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M...
Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
12 mars 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces $25 Million Private Placement
23 févr. 2021 07h45 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
17 févr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia
12 févr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Participate in Two Upcoming Investor Conferences
10 févr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Reaches Two Million Test Milestone
20 janv. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Provides Financial Guidance for Full-year 2021
13 janv. 2021 16h05 HE
|
Progenity, Inc.
Total 2021 revenue expected to grow by up to 30%1, reaching a range of $130 to $145 million Core molecular testing2 volume expected to grow by up to 16% SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE)...
Progenity to Present at the 2021 ICR Conference
05 janv. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Expands Availability of COVID-19 PCR Testing Services Across United States
17 déc. 2020 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...